Search

Your search keyword '"Sereno Moyano, M."' showing total 34 results
Start Over Author "Sereno Moyano, M."
34 results on '"Sereno Moyano, M."'

1. MA14.12 Characterization of Sexual Dysfunction in Patients with Lung Cancer Undergoing Oncological Management: Results from the LUDICAS Study

Author

Serrano, A.V. Ospina, Azkona, E., Guillén Sentís, P., Aparisi, F., López Castro, R., Cruz, P., Valdivia, A., Cordeiro, P., Olivares Hernández, A., Dómine, M., Antoñanzas Basa, M., Blasco, A., Peralta, D., Sereno Moyano, M., Cardeña Gutiérrez, A., Romão, R., Losada Vila, B., Avendaño, A., Arango, N., Ramos, P., Guirado Risueño, M., Muñoz, S., Cuello, J., Campos Balea, B., Triana, I.C., and Provencio, M.

Published
2024
Full Text
View/download PDF

2. Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront [FP07.06]

Author

Blanc-Durand, F., Mielgo Rubio, X., Auclin, E., Ponce-Aix, S., Lopez Castro, R., Nadal, E., Planchard, D., Routy, B., Hendriks, L., Sullivan, I., Dempsey, N., Pilotto, S., Aboubakar Nana, Frank, Pinato, D.J., Castonguay, M., Rodriguez, A., Amores, A., Bluthgen, M.V., Duchemann, B., Castellano, P. Cruz, Aguado De La Rosa, C., Sereno Moyano, M., Ruffinelli, J., Lopez, G., Caramella, C., Besse, B., Mezquita, L., 2020 World Conference on Lung Cancer, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (SLuc) Service de pneumologie

Subjects
Pulmonary and Respiratory Medicine, Oncology
Abstract

INTRODUCTION : The Lung Immune Prognostic Index (LIPI) that combines the neutrophils/[leucocytes minus neutrophils] ratio (dNLR) and lactate dehydrogenase (LDH), is associated with outcomes in pretreated advanced NSCLC patients receiving single agent immune checkpoint inhibitors (ICI). However, its role in first line treatment of advanced NSCLC patients has not been explored yet. We assessed the value of baseline LIPI in the first line setting, for ICI-monotherapy, ICI-combination or platinum-based chemotherapy alone (CT). [...]

Published
2021

3. Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront [FP07.06]

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Blanc-Durand, F., Mielgo Rubio, X., Auclin, E., Ponce-Aix, S., Lopez Castro, R., Nadal, E., Planchard, D., Routy, B., Hendriks, L., Sullivan, I., Dempsey, N., Pilotto, S., Aboubakar Nana, Frank, Pinato, D.J., Castonguay, M., Rodriguez, A., Amores, A., Bluthgen, M.V., Duchemann, B., Castellano, P. Cruz, Aguado De La Rosa, C., Sereno Moyano, M., Ruffinelli, J., Lopez, G., Caramella, C., Besse, B., Mezquita, L., 2020 World Conference on Lung Cancer, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Blanc-Durand, F., Mielgo Rubio, X., Auclin, E., Ponce-Aix, S., Lopez Castro, R., Nadal, E., Planchard, D., Routy, B., Hendriks, L., Sullivan, I., Dempsey, N., Pilotto, S., Aboubakar Nana, Frank, Pinato, D.J., Castonguay, M., Rodriguez, A., Amores, A., Bluthgen, M.V., Duchemann, B., Castellano, P. Cruz, Aguado De La Rosa, C., Sereno Moyano, M., Ruffinelli, J., Lopez, G., Caramella, C., Besse, B., Mezquita, L., and 2020 World Conference on Lung Cancer

Abstract

INTRODUCTION : The Lung Immune Prognostic Index (LIPI) that combines the neutrophils/[leucocytes minus neutrophils] ratio (dNLR) and lactate dehydrogenase (LDH), is associated with outcomes in pretreated advanced NSCLC patients receiving single agent immune checkpoint inhibitors (ICI). However, its role in first line treatment of advanced NSCLC patients has not been explored yet. We assessed the value of baseline LIPI in the first line setting, for ICI-monotherapy, ICI-combination or platinum-based chemotherapy alone (CT). [...]

Published
2021

5. FP12.01 Circulating Tumor DNA to the Identification of EGFR Positive NSCLC Long-Term Survivors

Author

Franco, F., primary, Serna-Blasco, R., additional, Sanchez-Hernandez, A., additional, De Julian Campayo, M., additional, Giron, C. Garcia, additional, Dómine Gómez, M., additional, Blasco, A., additional, Sanchez, J.M., additional, Oramas, J., additional, Bosch-Barrera, J., additional, Sala, M., additional, Sereno Moyano, M., additional, Ortega Granados, A.L., additional, Chara, L.E., additional, Hernandez, B., additional, Padilla, A., additional, Coves, J., additional, Blanco, R., additional, Balsalobre, J., additional, Mielgo Rubio, X., additional, Bueno, C., additional, Auglyte, M., additional, Calvo, V., additional, Romero, A., additional, and Provencio, M., additional

Published
2021
Full Text
View/download PDF

6. FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.

Author

Blanc-Durand, F., primary, Mielgo Rubio, X., additional, Auclin, E., additional, Ponce-Aix, S., additional, Lopez Castro, R., additional, Nadal, E., additional, Planchard, D., additional, Routy, B., additional, Hendriks, L., additional, Sullivan, I., additional, Dempsey, N., additional, Pilotto, S., additional, Aboubakar, F., additional, Pinato, D.J., additional, Castonguay, M., additional, Rodriguez, A., additional, Amores, A., additional, Bluthgen, M.V., additional, Duchemann, B., additional, Castellano, P. Cruz, additional, Aguado De La Rosa, C., additional, Sereno Moyano, M., additional, Ruffinelli, J., additional, Lopez, G., additional, Caramella, C., additional, Besse, B., additional, and Mezquita, L., additional

Published
2021
Full Text
View/download PDF

7. 1752P Epidemiological analysis of SARS-CoV-2 virus infection in patients with solid tumors: The experience of Infanta Sofía University Hospital (HUIS)

Author

Gomez Raposo, C., primary, Falagán, S., additional, Andreu-Vázquez, C., additional, Thuissard, I.J., additional, García Fernández, C., additional, Aguayo Zamora, C., additional, Jiménez Gordo, A.M., additional, López Gómez, M., additional, Merino Salvador, M., additional, Sandoval, C., additional, Sereno Moyano, M., additional, Zambrana, F., additional, Roa Franco, S., additional, Martín Domínguez, C., additional, Moreno Rubio, J., additional, and Casado, E., additional

Published
2020
Full Text
View/download PDF

8. Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer

Author

Lopez Castro, R., primary, Lianes, P., additional, Nogueron Martnez, E., additional, Diz Tain, P., additional, Calzas, J., additional, Juan Vidal, O.J., additional, Sereno Moyano, M., additional, Muñoz, M.A., additional, Guillot Morales, M., additional, Capdevila Riera, L., additional, Campillo Fuentes, J.A., additional, Valdivia-Bautista, J., additional, Cobo Dols, M., additional, Paredes Lario, A., additional, Mielgo Rubio, X., additional, Majem Tarruella, M., additional, Martínez, M., additional, Sanchez Torres, J.M., additional, Rubio-Viqueira, B., additional, and Provencio, M., additional

Published
2019
Full Text
View/download PDF

9. SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz)

Author

Valderrama, B.P., primary, Perez Ramirez, S., additional, Rodriguez-Vida, A., additional, González del Alba, A., additional, Mendez Vidal, M.J., additional, Vazquez Estevez, S., additional, Martinez Ortega, E., additional, Virizuela, J.A., additional, Fernández Calvo, O., additional, Hernández Jorge, A., additional, Vazquez Mazon, F.J., additional, Gonzalez Gragera, M.B., additional, Campayo, M., additional, Etxaniz Ulazia, O., additional, Almagro Casado, E., additional, Sereno Moyano, M., additional, Abad Villar, M.T., additional, Suarez Rodriguez, C., additional, Gallardo Diaz, E., additional, and Arranz Arija, J.A., additional

Published
2019
Full Text
View/download PDF

10. P3.01-88 Clinical and Molecular Analysis of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid

Author

Sereno Moyano, M., primary, Falagan, S., additional, Moreno Rubio, J., additional, Álvarez Álvarez, R., additional, Olmedo, M.E., additional, Mielgo, X., additional, Navarro, F., additional, Ramos, R., additional, Enguita, A.B., additional, Benito, A., additional, Cebollero, M., additional, Alemany, I., additional, Castillo, C., additional, Casado, E., additional, and Ponce Aix, S., additional

Published
2018
Full Text
View/download PDF

11. P1.01-69 Validation of the Lung Immune Prognostic Index (LIPI): Useful to Identify Resistance to PD-1 Checkpoint Inhibitors in Pretreated Lung Cancer

Author

Mielgo-Rubio, X., primary, Sereno Moyano, M., additional, Sotelo-Lezama, M., additional, Lopez Castro, R., additional, Rubio-Martínez, J., additional, Velastegui, A., additional, Olier-Garate, C., additional, Falagan, S., additional, Gómez-Barreda, I., additional, Riquelme, A., additional, Cardeña-Gutiérrez, A., additional, Moreno Rubio, J., additional, López, C., additional, Bueno, C., additional, Silva-Ruiz, J., additional, Zhan Zhou, E., additional, and Chara, L., additional

Published
2018
Full Text
View/download PDF

12. Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients

Author

Mielgo Rubio, X., primary, Sereno Moyano, M., additional, Chara, L.E., additional, López-Castro, R., additional, Rubio-Martínez, J., additional, Velastegui, A., additional, Olier-Garate, C., additional, Falagán, S., additional, Gómez-Barreda, I., additional, Riquelme, A., additional, Silva-Ruiz, J., additional, Moreno-Rubio, J., additional, López, C., additional, Bueno, C., additional, Cardeña, A., additional, Pérez-Fernández, E., additional, Martí-Castelló, M.P., additional, and Sotelo-Lezama, M.J., additional

Published
2018
Full Text
View/download PDF

13. Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)

Author

Gajate Borau, P., primary, Martin Marino, A., additional, Gallegos Sancho, I., additional, Villa Guzman, J.C., additional, Velastegui, A., additional, Alonso Gordoa, T., additional, Castellano, D., additional, Rubio Romero, G., additional, Pinto Marin, A., additional, Villalobos Leon, L., additional, Maximiano Alonso, C., additional, Sotelo-Lezama, M.J., additional, Sereno Moyano, M., additional, Rodríguez, J.F., additional, Perezagua Marin, C., additional, Ballesteros, J., additional, Marrupe Gonzalez, D., additional, Rodriguez Lajusticia, L., additional, Tafalla García, J.J., additional, and Aguado, C., additional

Published
2018
Full Text
View/download PDF

14. GECP 1605/NIVEX TRIAL nivolumab in the real world: The SPANISH expanded access program experience in pretreated advanced NSCLC

Author

Majem Tarruella, M., primary, Campillo, J., additional, Grau Béjar, J.F., additional, Carcereny, E., additional, Bernabe Caro, R., additional, Garcia, Y., additional, Artal-Cortes, A., additional, González Cao, M., additional, Lianes, P., additional, Paredes Lario, A., additional, Sereno Moyano, M., additional, Mielgo Rubio, X., additional, Macias, J.A., additional, Provencio Pulla, M., additional, and Rodriguez-Abreu, D., additional

Published
2018
Full Text
View/download PDF

15. MA10.01 Antibiotic Use and PD-1 Inhibitors: Shorter Survival in Lung Cancer, Especially When Given Intravenously. Type of Infection Also Matters

Author

Mielgo-Rubio, X., primary, Chara, L., additional, Sotelo-Lezama, M., additional, Lopez Castro, R., additional, Rubio-Martínez, J., additional, Velastegui, A., additional, Olier-Garate, C., additional, Falagan, S., additional, Gómez-Barreda, I., additional, Bautista-Sanz, P., additional, Silva-Ruiz, J., additional, Moreno Rubio, J., additional, López, C., additional, Cardeña-Gutiérrez, A., additional, Pérez-Fernández, E., additional, and Sereno Moyano, M., additional

Published
2018
Full Text
View/download PDF

16. SPAZO2 (SOGUG): Validation of the international metastatic database consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC)

Author

Pérez-Valderrama, B., primary, Arranz Arija, J., additional, Chirivella González, I., additional, Anido Herranz, U., additional, Jurado García, J.M., additional, Suarez Rodriguez, C., additional, García Carbonero, I., additional, de Velasco, G., additional, García Domínguez, R., additional, García Marrero, R.D., additional, Gonzalez Del Alba Baamonde, M.A., additional, Molins Palau, C., additional, Lazaro, M.E., additional, Munoz-Langa, J., additional, Martinez Ortega, E., additional, Hernández Jorge, A., additional, Campayo Guillaumes, M., additional, Sereno Moyano, M., additional, Luque Caro, R., additional, and Rodríguez Sánchez, Á., additional

Published
2017
Full Text
View/download PDF

17. 1848P - Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer

Author

Lopez Castro, R., Lianes, P., Nogueron Martnez, E., Diz Tain, P., Calzas, J., Juan Vidal, O.J., Sereno Moyano, M., Muñoz, M.A., Guillot Morales, M., Capdevila Riera, L., Campillo Fuentes, J.A., Valdivia-Bautista, J., Cobo Dols, M., Paredes Lario, A., Mielgo Rubio, X., Majem Tarruella, M., Martínez, M., Sanchez Torres, J.M., Rubio-Viqueira, B., and Provencio, M.

Published
2019
Full Text
View/download PDF

18. 954P - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz)

Author

Valderrama, B.P., Perez Ramirez, S., Rodriguez-Vida, A., González del Alba, A., Mendez Vidal, M.J., Vazquez Estevez, S., Martinez Ortega, E., Virizuela, J.A., Fernández Calvo, O., Hernández Jorge, A., Vazquez Mazon, F.J., Gonzalez Gragera, M.B., Campayo, M., Etxaniz Ulazia, O., Almagro Casado, E., Sereno Moyano, M., Abad Villar, M.T., Suarez Rodriguez, C., Gallardo Diaz, E., and Arranz Arija, J.A.

Published
2019
Full Text
View/download PDF

20. 1413P - Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients

Author

Mielgo Rubio, X., Sereno Moyano, M., Chara, L.E., López-Castro, R., Rubio-Martínez, J., Velastegui, A., Olier-Garate, C., Falagán, S., Gómez-Barreda, I., Riquelme, A., Silva-Ruiz, J., Moreno-Rubio, J., López, C., Bueno, C., Cardeña, A., Pérez-Fernández, E., Martí-Castelló, M.P., and Sotelo-Lezama, M.J.

Published
2018
Full Text
View/download PDF

21. 823P - Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)

Author

Gajate Borau, P., Martin Marino, A., Gallegos Sancho, I., Villa Guzman, J.C., Velastegui, A., Alonso Gordoa, T., Castellano, D., Rubio Romero, G., Pinto Marin, A., Villalobos Leon, L., Maximiano Alonso, C., Sotelo-Lezama, M.J., Sereno Moyano, M., Rodríguez, J.F., Perezagua Marin, C., Ballesteros, J., Marrupe Gonzalez, D., Rodriguez Lajusticia, L., Tafalla García, J.J., and Aguado, C.

Published
2018
Full Text
View/download PDF

22. 895P - SPAZO2 (SOGUG): Validation of the international metastatic database consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC)

Author

Pérez-Valderrama, B., Arranz Arija, J., Chirivella González, I., Anido Herranz, U., Jurado García, J.M., Suarez Rodriguez, C., García Carbonero, I., de Velasco, G., García Domínguez, R., García Marrero, R.D., Gonzalez Del Alba Baamonde, M.A., Molins Palau, C., Lazaro, M.E., Munoz-Langa, J., Martinez Ortega, E., Hernández Jorge, A., Campayo Guillaumes, M., Sereno Moyano, M., Luque Caro, R., and Rodríguez Sánchez, Á.

Published
2017
Full Text
View/download PDF

28. [A supernumerary bone].

Author

Gutiérrez-Gutiérrez G and Sereno Moyano M

Subjects
Adult, Foreign Bodies etiology, Humans, Male, Radiography, Foreign Bodies diagnostic imaging, Rectum diagnostic imaging, Sexual Behavior
Published
2012
Full Text
View/download PDF

29. Male breast cancer.

Author

Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M, López Gómez M, and Casado E

Subjects
Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Combined Modality Therapy, Female, Humans, Male, Mastectomy, Radiotherapy, Risk Factors, Breast Neoplasms, Male genetics, Breast Neoplasms, Male therapy
Abstract

Male breast cancer accounts for around 1% of all breast cancer cases, but the incidence has increased over the past 25 years. The rarity of this entity precludes prospective randomized clinical trials. Although breast carcinoma in both genders share certain characteristics, notable differences have emerged. Familial cases usually have BRCA2 rather than BRCA1 mutations. Klinefelter syndrome is the strongest risk factor for developing male breast carcinoma. Men tend to be diagnosed at an older age than women. Presentation is usually a painless lump, but is often late, with more than 40% of individuals having stage III or IV disease. When survival is adjusted for age at diagnosis and stage of disease, outcomes for male and female patients with breast cancer is similar. Surgery is usually mastectomy with axillary clearance or sentinel node biopsy. Because 90% of tumors are hormonal receptor positive, tamoxifen is standard adjuvant therapy. Indications for radiotherapy and chemotherapy are similar to female breast cancer. For metastatic disease, hormonal therapy is the main treatment, but chemotherapy can also provide palliation., (2010 Elsevier Ltd. All rights reserved.)

Published
2010
Full Text
View/download PDF

30. The combination of FOLFOX4 and bevacizumab may enable salvage surgery of unresectable liver metastases in colon cancer.

Author

Sereno Moyano M, Casado Sáenz E, de Castro-Carpeño J, and Belda-Iniesta C

Abstract

Colorectal cancer treatment has experienced important advances in the last 5 years. New targeted therapies have been included in the classical regimens based on 5-fluorouracil, oxaliplatin, or irinotecan. This new approach has brought great revolution in the treatment of this type of cancer. Bevacizumab (Avastin), a new antivascular endothelial growth factor drug, has been shown to improve overall survival in combination with chemotherapy in first-line and second-line settings as compared with standard chemotherapy regimens alone. This case report demonstrates our experience with bevacizumab in a colon cancer patient with liver, lung, and regional lymph node metastases who had a relapse in the liver after adjuvant treatment with capecitabine (Xeloda). The addition of bevacizumab to the FOLFOX4 regimen resulted in a partial response that provided an opportunity for salvage hepatic surgery.

Published
2009
Full Text
View/download PDF

31. Idiopathic and recurrent thromboembolic phenomena in cancer patients.

Author

López-Gómez M, Gómez-Raposo C, Sereno Moyano M, Casado-Sáenz E, Feliú Batlle J, Ortega Ruipérez C, and González Barón M

Subjects
Aged, Anticoagulants therapeutic use, Female, Humans, Incidence, Male, Middle Aged, Neoplasms therapy, Recurrence, Venous Thromboembolism diagnosis, Venous Thromboembolism drug therapy, Neoplasms diagnosis, Neoplasms epidemiology, Neoplasms etiology, Venous Thromboembolism complications, Venous Thromboembolism epidemiology
Abstract

Background: Venous thromboembolism (VTE) is one of the most common complications in cancer patients. It is not only associated with both reduced survival and a high number of recurrences, but an idiopathic VTE also increases the likelihood of a cancer diagnosis., Methods: Between January 2000 and October 2005 we reviewed the medical history of 88 patients who were admitted to a tertiary hospital and presented both a diagnosis of VTE and any type of tumour. The information collected included the type of tumour, the temporal association between tumour diagnosis and VTE, anticoagulation treatment applied and percentage of recurrences., Results: Ten patients (11.4%) presented the VTE prior to the cancer diagnosis; only half of them underwent a posterior tumour screening routine. Fifteen patients (17%) were diagnosed simultaneously and 71% presented the VTE after the tumour was detected. In 47 patients (53.4%) no risk factors for VTEs were detected. Twenty-nine patients (31.7%) presented a recurrent VTE, mainly during chemotherapy treatment (66%). Less than half of the patients (47.57%) were receiving treatment with low-molecular- weight heparins (LMWH)., Conclusions: Idiopathic VTEs may be the first manifestation of an occult neoplasia, but tumour screening is scheduled in only a few patients. Regarding the high incidence of recurrent VTE in cancer populations, a high percentage is attributed to the underuse of LMWH, whose efficacy in preventing recurrent phenomena is superior to oral dicumarinics.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results